dr. F.A. Holtkamp

No picture available
f.a.holtkamp umcg.nl


  1. Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints

    Rossignol, P., Agarwal, R., Canaud, B., Charney, A., Chatellier, G., Craig, J. C., Cushman, W. C., Gansevoort, R. T., Fellström, B., Garza, D., Guzman, N., Holtkamp, F., London, G. M., Massy, Z. A., Mebazaa, A., Mol, P., Pfeffer, M. A., Rosenberg, Y., Ruilope, L. M., Seltzer, J., Shah, A. M., Shah, S., Singh, B., Stefánsson, B. V., Stockbridge, N., Stough, W. G., Thygesen, K., Walsh, M., Wanner, C., Warnock, D. G., Wilcox, C. S., Wittes, J., Pitt, B., Thompson, A. & Zannad, F., 14-Mar-2019, In : European Heart Journal. 40, 11, p. 880-887 8 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors

    Blind, E., de Graeff, P. A., Meurs, I., Holtkamp, F., Baczynska, A. & Janssen, H., 27-Dec-2015, In : European Heart Journal. 37, 6, p. 502-503 2 p.

    Research output: Contribution to journalEditorialAcademicpeer-review

  3. Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome

    Kröpelin, T. F., de Zeeuw, D., Holtkamp, F. A., Packham, D. K. & Heerspink, H. J. L., Sep-2016, In : Nephrology, Dialysis, Transplantation. 31, 9, p. 1471-1477 7 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Safety information on QT-interval prolongation: Comparison of European Union and United States drug labeling

    Warnier, M. J., Holtkamp, F. A., Rutten, F. H., Hoes, A. W., de Boer, A., Mol, P. G. M. & De Bruin, M. L., Sep-2014, In : Drug Discovery Today. 19, 9, p. 1294-1297 4 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

View all (11) »

ID: 284115